Fresenius (FMS) told Reuters in a statement that Novo Nordisk’s (NVO) Ozempic and other GLP-1 drugs could slow the progression of Chronic Kidney Disease, but mortality would also be reduced. Fresenius added that it assesses the overall effect of GLP-1 analogue use on its own patient flow model as neutral.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FMS:
